Human TREM2 Protein, His Tag

Customer Reviews
Cat. No. / Size
Price
Qty
TR2-H52H5-100ug
$385.00
TR2-H52H5-1mg
$2615.00
ETA of in-stock products:2 business days

Product Details

  • Synonym

    Triggering receptor expressed on myeloid cells 2, TREM2, TREM-2

  • Source

    Human TREM2, His, Tag (TR2-H52H5) is expressed from human 293 cells (HEK293). It contains AA His 19 - Ser 174 (Accession # Q9NZC2-1).

    Predicted N-terminus: His 19

    Request for sequence
  • Molecular Characterization

    TREM2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 19.3 kDa. The protein migrates as 27-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    TREM2 SDS-PAGE

    Human TREM2, His, Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     TREM2 ELISA

    Immobilized Human TREM2, His, Tag (Cat. No. TR2-H52H5) at 1 μg/mL (100 μL/well) can bind Anti-TREM2 Antibody, Human IgG1 with a linear range of 0.3-2 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     TREM2 SPR

    Anti-TREM2 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TREM2, His Tag (Cat. No. TR2-H52H5) with an affinity constant of 95.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor of the immunoglobulin superfamily. The TREM2 is found in various tissue macrophages, such as CNS microglia, bone osteoclasts, alveolar, peritoneal and intestinal macrophages. TREM2 is also present on cultured bone marrow-derived macrophages and monocyte-derived dendritic cells. Some research have identified a rare variant of TREM2 that is a risk factor for Alzheimer disease (AD), which is the most common form of late-onset dementia.The extracellular region of TREM2 contains a single immunoglobulin superfamily domain and binds polyanionic ligands, such as bacterial lipopolysaccharide (LPS) and phospholipids8. Upon ligand binding, TREM2 transmits intracellular signals through an adaptor, DAP12 (also known as TYRO protein tyrosine kinase-binding protein (TYROBP)), which is associated with the transmembrane region of TREM2 and which recruits the protein tyrosine kinase SYK through its cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs). TREM2 is a pro-tumorigenic marker of tumor-infiltrating macrophages in mouse models and human tumors that can be targeted to curb tumor growth and improve the efficacy of checkpoint blockade therapy while remodeling the landscape of tumor-infiltrating macrophages.

Recent Advances

 
Drug Development Progress
  • English Name:

    Triggering receptor expressed on myeloid cells 2

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    4 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland